Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. - Wikidata - awgldk - TriplyDB

Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.

Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.

http://www.wikidata.org/entity/Q45083293

about

Ranolazine: A Contemporary Review A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve Microvascular angina: angina that predominantly affects women Coronary microvascular dysfunction, microvascular angina, and treatment strategies.Pharmacotherapy for coronary microvascular dysfunction Sex differences in the pathophysiology, treatment, and outcomes in IHD Management standards for stable coronary artery disease in India.Resolution of angina pectoris and improvement of the coronary flow reserve after ranolazine treatment in a woman with isolated impaired coronary microcirculation.Sex-specific factors in microvascular angina.Cardiac Syndrome X: update 2014.Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.Evolving strategies for the treatment of microvascular angina in women.Coronary microvascular dysfunction: an update Current Diagnostic and Therapeutic Strategies in Microvascular Angina.Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management Microvascular coronary dysfunction and ischemic heart disease: where are we in 2014?Anti-anginal and anti-ischemic effects of late sodium current inhibition Myocardial ischemia in women: lessons from the NHLBI WISE study.Therapy for stable angina in women Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.Reproducibility of myocardial perfusion reserve - variations in measurements from post processing using commercially available software.Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls.Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.Gender disparity in cardiovascular disease: bias or biology?Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.Ranolazine: clinical applications and therapeutic basis.Management of microvascular angina pectoris.Treatment of refractory angina in patients not suitable for revascularization.Microvascular angina: an update on diagnosis and treatment.Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function Vasotonic Angina as a Cause of Myocardial Ischemia in Women.Sex-Specific Disparities in Risk Factors for Coronary Heart Disease.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.Alternative causes of myocardial ischemia in women: An update on spontaneous coronary artery dissection, vasospastic angina and coronary microvascular dysfunction.Deciphering cardiac involvement in systemic inflammatory diseases: noninvasive tissue characterisation using cardiac magnetic resonance is key to improved patients' care.Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction.Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update.Ranolazine for stable angina pectoris.Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.

P2860

Q26765421-2351EBB9-4BDD-4A61-BFD2-43B18877B105 Q26776330-9DC367BF-053A-420B-8422-601A701286CF Q26860185-B5B01429-B754-456A-A5C7-005A42AADA24 Q26861073-AF49D9D3-01E2-46FB-BE9C-D21751B6DF90 Q26991627-8B6D2FD1-DDE4-4986-9759-94DA173B3230 Q28084204-4F2D1D81-3A66-4BA1-80FC-F6765C670B59 Q30239853-C6011EA0-03FA-46CB-9BD9-1671861D2E82 Q33559253-627DF4BF-D997-4B9F-A58E-9F50CD435AAA Q33818831-3EE20B57-1C5C-480C-BDFD-22C295B345C1 Q34007353-A69234D0-461E-4C36-BF03-16F40B96D772 Q34313090-4CE3BD49-2AA1-4F70-9710-F5C4EF8139EE Q34317991-5981DCB0-68B1-4514-8EB1-D221189A0392 Q34658569-ADC16EDA-7835-44BB-B5A5-95B51EADBA26 Q35077560-4F5A07E4-A90F-4FE5-A951-87EEB808E7E5 Q35093085-99D65C55-7E9A-4837-AAB1-D8DEAC8F4529 Q35108848-201B7823-EF79-4B87-BB29-2365757061AF Q35147202-FC342BCB-56EE-4E30-9209-96C6D0FD4D51 Q35816400-66FF2FB2-375B-486F-B2E9-37503877EBC8 Q36137967-933C7D0D-DB55-4AF4-80CF-99B7BBCE6940 Q37199774-BEADD572-BC90-4A6F-8105-5384A67B518A Q37339320-281E07C3-1376-4C54-B2B4-20BCED9A91A0 Q37339422-5D06DAD8-EFEB-4772-8AE8-819FAAB58E35 Q38057398-0C91EFB7-6BAC-4C33-95EF-1EC70EFB1F27 Q38067775-056C7533-121D-4295-B313-0BAB22682199 Q38074900-4FF5D187-1275-4A29-804D-F8E6250FCCD7 Q38075519-356A89CB-09F1-4D45-BD45-BAC05B139D93 Q38156702-CF59732B-8C0B-4B90-BBD9-02CBAB149AF0 Q38173640-97ED3C6B-7ABC-42D9-991B-3B660419DECA Q38373871-88B4914E-6D25-4CF5-ADFA-BFBCF87E1FEF Q38377198-EF5A380F-D827-4E08-8365-03F85C044FEB Q38504653-1F55E035-F3C6-4EB1-8DFF-8B81481CB90F Q38537278-331D2DD2-D57B-475C-8661-41C4BE8AF0CD Q38614176-D3EEBDC9-40D4-4A32-AB23-3913B3AD2BA2 Q38663003-3488478D-CA16-4A72-8AB7-DC676F8A42DB Q38692393-ABBF919F-86A2-4903-B34D-AA2774136958 Q38830086-EB3B4A68-167C-4C77-8899-83E349DEEB62 Q38846938-0C56A808-E478-41B7-BCA9-AC1EBD12FA65 Q38920729-9DBDB9E9-A710-4AE4-A7FD-DD36661DB46B Q38971758-5743610B-032A-4A2B-817B-9BA4BDE122E0 Q39176512-B5A76C5B-9AE4-4AAE-BF21-60C79A55D8DC

P2860

Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.

http://www.wikidata.org/entity/Q45083293

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Ranolazine improves angina in ...... ctive coronary artery disease.

@en

Ranolazine improves angina in ...... ctive coronary artery disease.

@nl

type

label

Ranolazine improves angina in ...... ctive coronary artery disease.

@en

Ranolazine improves angina in ...... ctive coronary artery disease.

@nl

prefLabel

Ranolazine improves angina in ...... ctive coronary artery disease.

@en

Ranolazine improves angina in ...... ctive coronary artery disease.

@nl

P1433

Q45083293-2F422B75-B7EC-44A0-AEED-E6168CC7DB10

P1476

Q45083293-A0518D23-C0D7-42E3-AE2C-173573B3C041

P2093

Q45083293-04B21802-8A69-4D7C-B53F-CD3616FB1E9F

Q45083293-09417160-E2C0-4A00-A29D-F860240A607A

Q45083293-0C745C69-A64C-4FA6-A828-B3557A254B00

Q45083293-2E7EA195-8D9F-4E50-B903-AB4C46C635FB

Q45083293-3ECF278B-5043-4602-861E-536AC44542C8

Q45083293-43A48E7B-F0CF-4A2D-B5AE-B452735E6551

Q45083293-504A1CB8-DC6C-4596-83C5-1774CB4C7A3E

Q45083293-64D194C7-9A3B-4F17-A747-1C082B40BCC5

Q45083293-692A7DD2-1C2E-44E8-9412-8B50C65254E4

Q45083293-D5C6D938-6CF7-4500-9850-0F02E0F5A892

P304

Q45083293-CB4A3E1A-92D4-4822-89A5-368FB3030545

P31

Q45083293-AA4AE2DE-8D2D-4A05-BA19-0CE1016BA735

P356

Q45083293-FD0FA70A-D16B-41C4-9841-D10C7D79EB79

P433

Q45083293-7CED90A7-E677-4A25-ACC5-4792D17DC719

P478

Q45083293-A853F078-75FF-4A47-9E74-987D54A256C3

P50

Q45083293-385A13B5-1AB5-4236-8EBE-66B717736F04

P577

Q45083293-07EAA59B-D994-4414-BDE3-2DA91D61B78D

P5875

Q45083293-0E791770-66DB-485A-8EB8-4F79F710B4C3

P698

Q45083293-AF52DF6A-C2AF-4522-B1AE-34D5FFE3152E

P932

Q45083293-9F6C8F8E-FDC8-4C67-900D-34A604CD13D9

P356

J.JCMG.2011.03.007

P1433

JACC: Cardiovascular Imaging

P1476

Ranolazine improves angina in ...... uctive coronary artery disease

@en

P2093

Chrisandra Shufelt

http://www.w3.org/2001/XMLSchema#string

Daniel S Berman

http://www.w3.org/2001/XMLSchema#string

Edward Gill

http://www.w3.org/2001/XMLSchema#string

Janet Wei

http://www.w3.org/2001/XMLSchema#string

Leslee J Shaw

http://www.w3.org/2001/XMLSchema#string

Louise E J Thomson

http://www.w3.org/2001/XMLSchema#string

Margo Minissian

http://www.w3.org/2001/XMLSchema#string

Melissa Slivka

http://www.w3.org/2001/XMLSchema#string

Pavel Goykhman

http://www.w3.org/2001/XMLSchema#string

Piotr J Slomka

http://www.w3.org/2001/XMLSchema#string

P304

514-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCMG.2011.03.007

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

C Noel Bairey-Merz

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51120536

http://www.w3.org/2001/XMLSchema#string

P698

21565740

http://www.w3.org/2001/XMLSchema#string

P932

6364688

http://www.w3.org/2001/XMLSchema#string